Epizyme, inc. (EPZM)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Revenue:
Total revenue

-

23,800

29,206

35,491

-

0

-

0

-

-

-

0

-

8,007

8,084

1,858

2,121

2,560

12,354

20,173

28,931

41,411

67,379

67,646

72,991

68,482

41,060

47,947

48,450

45,222

0

0

0

Total revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of product revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

130,906

132,639

116,220

116,668

107,107

105,833

112,928

114,642

110,588

109,661

109,111

104,258

98,416

91,461

79,897

72,797

71,898

111,209

114,895

120,351

117,299

75,595

70,775

63,115

59,553

57,567

52,980

47,654

42,616

38,483

0

0

0

Selling, general and administrative

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

68,303

56,943

51,382

-

43,972

40,233

38,016

38,272

37,181

36,330

34,541

30,795

28,372

26,809

25,963

24,509

23,900

22,818

21,811

21,147

20,866

20,309

18,227

16,000

14,042

11,996

10,039

8,598

7,507

0

0

0

Total operating expenses

214,764

200,942

173,163

168,050

153,705

149,805

153,161

152,658

148,860

146,842

145,441

138,799

129,211

119,833

106,706

98,760

96,407

135,109

137,713

142,162

138,446

96,461

91,084

81,342

75,553

71,609

64,976

57,693

51,214

45,990

0

0

0

Operating loss

-197,501

-177,142

-143,957

-144,559

-124,114

-128,105

-141,161

-140,658

-138,860

-136,842

-134,963

-121,737

-121,676

-111,826

-98,622

-96,902

-94,286

-132,549

-125,359

-121,989

-109,515

-55,050

-23,705

-13,696

-2,562

-3,127

-23,916

-9,746

-2,764

-768

0

0

0

Other income, net:
Interest income, net

6,208

7,110

7,236

6,426

5,316

4,557

3,923

3,341

2,626

2,165

1,791

1,773

1,749

1,531

1,130

681

283

94

86

90

110

95

0

0

0

-

-

-

-

-

-

-

-

Other (expense), net

-55

-13

-60

-51

-49

-25

51

25

46

32

13

66

72

83

70

70

74

79

79

75

67

59

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense related to sale of future royalties

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

5,666

6,905

7,176

6,375

5,267

4,532

3,974

3,366

2,672

2,197

1,804

1,839

1,821

1,614

1,200

751

357

173

165

165

177

154

132

114

41

-7

-34

-52

34

67

0

0

0

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-3,134

-23,950

-9,798

-2,730

-701

0

0

0

Income tax (provision) benefit

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

349

1

0

0

0

-

-

-

Net loss

-191,893

-170,295

-136,838

-138,241

-118,904

-123,630

-136,851

-136,956

-135,852

-134,309

-133,159

-119,898

-119,855

-110,212

-97,422

-96,151

-93,929

-132,376

-125,185

-121,820

-109,447

-55,005

-24,040

-14,044

-2,870

-3,483

-23,951

-9,799

-2,731

-702

0

0

0

Other comprehensive income (loss):
Unrealized (loss) gain on available-for-sale securities

-107

73

172

274

104

-5

8

34

22

57

-45

-49

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-192,000

-170,222

-136,666

-137,967

-118,800

-123,635

-136,843

-136,922

-135,830

-134,252

-133,095

-119,983

-119,949

-110,318

-97,517

-96,126

-93,929

-132,376

-125,185

-121,820

-109,447

-55,005

0

0

0

-

-

-

-

-

-

-

-

Reconciliation of net loss to net loss attributable to common stockholders:
Net loss

-191,893

-170,295

-136,838

-138,241

-118,904

-123,630

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of convertible preferred stock

-

2,940

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

264

424

583

632

486

0

0

0

Net loss attributable to common stockholders

-191,893

-173,235

-139,778

-141,181

-121,844

-123,630

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,751

-24,375

-14,354

-11,689

-9,514

0

0

0

Net loss per share attributable to common stockholders:
Basic

-0.51

-0.59

-

-

-0.39

-0.29

-

-

-

-0.51

-0.63

-0.48

-0.56

-0.61

-0.42

-0.49

-0.41

-0.38

-0.56

-0.63

-1.75

-0.44

-0.58

-0.40

-0.22

0.56

-0.34

-0.25

-4.27

-2.81

0.19

0.21

-3.38

Diluted

-0.51

-0.59

-

-

-0.39

-0.29

-

-

-

-0.51

-0.63

-0.48

-0.56

-0.61

-0.42

-0.49

-0.41

-0.38

-0.56

-0.63

-1.75

-0.44

-0.58

-0.40

-0.22

0.52

-0.34

-0.25

-4.27

-2.81

0.18

0.20

-3.38

Net loss per share attributable to common stockholders - basic and diluted

-

-

-0.40

-0.53

-

-

-0.54

-0.42

-0.49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding used in net loss per share attributable to common stockholders:
Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted

-

-

91,044

90,876

-

-

69,539

69,490

69,386

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic

99,616

95,074

-

-

82,424

78,962

-

-

-

69,389

59,899

58,377

58,219

58,033

57,970

57,352

55,149

41,816

41,461

41,087

34,992

34,273

33,676

33,156

30,959

28,434

28,406

9,146

1,791

1,670

1,651

1,636

1,623

Diluted

99,616

95,074

-

-

82,424

78,962

-

-

-

69,389

59,899

58,377

58,219

58,033

57,970

57,352

55,149

41,816

41,461

41,087

34,992

34,273

33,676

33,156

30,959

30,901

28,406

9,146

1,791

1,670

3,017

2,913

1,623

Product [Member]
Total revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration Revenue
Total revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-